Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration (MIP310)

This study has been completed.
Information provided by (Responsible Party):
Medtronic Diabetes Identifier:
First received: September 13, 2005
Last updated: September 19, 2011
Last verified: August 2011
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.

Condition Intervention Phase
Type 1 Diabetes
Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
Device: Medtronic MiniMed Implantable Pump System
Drug: Aventis HOE21PH U400
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Active Control, Multi-Center Study Comparing the Effect of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration on Glycemic Control and the Frequency of Severe Hypoglycemia

Resource links provided by NLM:

Further study details as provided by Medtronic Diabetes:

Primary Outcome Measures:
  • Change in HbA1c and Compared Between Groups [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]
    To determine whether Intra Peritoneal insulin delivery via MIP results in glycemic control that is equal to or superior (i.e. not inferior to) control with SC therapy (Ho : μ (IP) -μ (SC) ≥ 0.50% A1C), a repeated measures analysis of variance, adjusting for baseline A1C using SAS Proc Mixed was used to compare average A1C trends over time between the two treatment groups (19). Type 3 Least Square (LS) means for each group were assessed. The Estimate statement within SAS proc mixed was used to estimate contrasts among the LS means and confidence intervals for the contrasts.

  • Incidence of Severe Hypoglycemia Events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The total number of severe hypoglycemia events, defined as a clinical episode of hypoglycemia (resulting in seizure or coma, requiring hospitalization, intravenous glucose or glucagon administration), or any hypoglycemia that requires assistance from another person, compared between the two study arms from Baseline to 12 months.

Secondary Outcome Measures:
  • Average Daily Blood Glucose [ Time Frame: average from baseline to 12 months ] [ Designated as safety issue: No ]
    For each subject, a minimum of two blood glucose readings per day was required for calculation of the average daily mean. The overall mean of the mean for each subject for the measure time frame was then calculated. The mean of the results for all subjects in each group were then analyzed and compared between groups both at Baseline and 12 months.

  • Mean Amplitude of Glycemic Excursions (MAGE) [ Time Frame: average from baseline to 12 months ] [ Designated as safety issue: No ]
    MAGE was calculated by taking the arithmetic mean of BG excursions when both ascending and descending segments of the curve exceed one Standard Deviation of the average 24-hour BG value. MAGE was calculated for each subject using SMBG data from periods in which subjects had a minimum of 4 and maximum of 10 readings daily. The overall mean of the mean for each subject for the measure time frame was then calculated. The mean of the results for all subjects in each group were then analyzed and compared between groups both at Baseline and 12 months.

  • Low Blood Glucose Index (LBGI); [ Time Frame: average from baseline to 12 months ] [ Designated as safety issue: No ]
    4 to 10 daily blood glucose readings (BG) were required for this measure. LBGI was calculated from BG values collected for 30 days prior to Visit 2 and 30 days following Visits 5 and 7. The continuous measure was compared between the two treatment groups for the three periods with a repeated measures ANOVA using proc mixed. Type 3 least square means for each group were assessed and estimate statements used to make comparisons among the LS means and create confidence intervals on the contrasts.

Enrollment: 107
Study Start Date: June 2002
Study Completion Date: September 2008
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MiniMed Implantable insulin Pump (MIP)
The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Other Name: Human insulin injection (rDNA origin)
Device: Medtronic MiniMed Implantable Pump System
The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
Other Name: IP insulin pump system
Drug: Aventis HOE21PH U400
400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Other Names:
  • Aventis U400 insulin
  • Aventis ETP Insulin
No Intervention: Subcutaneous insulin arm (SC)
The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.

Detailed Description:
Implantable insulin delivery pumps have been shown to reduce the occurrence of severe hypoglycemia in Type 1 DM subjects, as demonstrated in numerous European studies. Glycemic control is difficult to attain in subjects using exogenous insulin due to the risk of severe hypoglycemia. This study is aimed at comparing the efficacy of intraperitoneal (IP) insulin therapy to intensive subcutaneous insulin therapy over a period of 12 months.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • Type 1 diabetes mellitus (American Diabetes Association definition)
  • HbA1c greater than or equal to 7.5%
  • Intensive insulin treatment for at least 3 months
  • Physical and intellectual ability to operate MIP system
  • Subject has been under the routine care of the investigator for at least two months prior to enrollment
  • Subject has a reliable support person (defined as a person who has daily contact with the subject and knows whom to contact in the event of an emergency).
  • Capability and willingness to perform self-monitoring of blood glucose at least four times daily for 9 months of the study and 7 times daily for 3 months of the study
  • Physical and intellectual ability to operate the MIP system and to comply with the data reporting requirements of the study.
  • Subject is willing to sign the informed consent form (approved by local Institutional Review Board and Medtronic MiniMed)

Exclusion Criteria:

  • The subject's insulin usage exceeds 66 units per day.
  • Severe complications such as advanced autonomic neuropathy, legal blindness, or symptomatic cardiovascular disease as evidenced by a cardiovascular episode within the last six months
  • Reside at or plan to travel to elevations above 8000 feet during the study period (commercial airline travel is acceptable)
  • Subject who is pregnant, of childbearing potential or lactating and is neither surgically sterile, using contraceptives (devices, oral or implanted) nor other physician approved contraceptive
  • The subject has any major concomitant disease or any physical or psychological disorder within the last five years, which might be considered life threatening, or which might confound the collection or interpretation of the study data
  • The subject has previously enrolled in or participated in an investigational drug or device study within the preceding 4 weeks
  • The subject has any condition that precludes him/her from completing the study requirements
  • Has plans for activities which require them to go 25 feet below sea level
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00211536

United States, California
Sansum Medical Research Institute
Santa Barbara, California, United States, 93105
United States, Colorado
University of Colorado Health Sciences Center
Aurora, Colorado, United States, 80010
United States, Missouri
Hellman & Rosen Endocrine Associates
North Kansas City, Missouri, United States, 64116
United States, Ohio
Cleveland Clinic
Wooser, Ohio, United States, 44195
United States, Texas
Diabetes & Glandular Disease Clinic
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Medtronic Diabetes
Study Director: Scott W Lee, MD Medtronic
  More Information

Responsible Party: Medtronic Diabetes Identifier: NCT00211536     History of Changes
Other Study ID Numbers: CE-025A6 
Study First Received: September 13, 2005
Results First Received: April 25, 2011
Last Updated: September 19, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Medtronic Diabetes:
Implantable Insulin Pump
Intraperitoneal Insulin Delivery

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on October 21, 2016